Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer

Journal of Clinical Oncology

Volumn 29, Issue 15, 2011, Pages 2020-2026

  Boike, Thomas P ^a,b,c   Lotan, Yair ^a,b,c   Cho, L Chinsoo ^a,b,c   Brindle, Jeffrey ^a,b,c   DeRose, Paul ^a,b,c   Xie, Xian Jin ^a,b,c   Yan, Jingsheng ^a,b,c   Foster, Ryan ^a,b,c   Pistenmaa, David ^a,b,c   Perkins, Alida ^a,b,c   Cooley, Susan ^a,b,c   Timmerman, Robert ^a,b,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Prairie Lakes Healthcare System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENEMA; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX; ARTICLE; BALLOON; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL EVALUATION; DISEASE SEVERITY; FOLLOW UP; GLEASON SCORE; HUMAN; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION DOSE; RADIATION FIELD; RADIATION INJURY; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT FAILURE; TREATMENT PLANNING;

AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOSURGERY; RADIOTHERAPY DOSAGE; RISK;

EID: 79956328867     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.4377     Document Type: Article

References (30)

1. Timmerman R, Paulus R, Galvin J, et al: Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303:1070-1076, 2010
2. Timmerman R, Papiez L, McGarry R, et al: Extracranial stereotactic radioablation: Results of a phase I study in medically inoperable stage I nonsmall cell lung cancer. Chest 124:1946-1955, 2003
3. Timmerman R, McGarry R, Yiannoutsos C, et al: Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 24:4833-4839, 2006 (Pubitemid 46630909)
4. Schefter TE, Kavanagh BD, Timmerman RD, et al: A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys 62:1371-1378, 2005 (Pubitemid 40982057)
5. Rusthoven KE, Kavanagh BD, Cardenes H, et al: Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 27:1572-1578, 2009
6. Fowler J, Chappell R, Ritter M: Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 50:1021-1031, 2001
7. Brenner DJ, Hall EJ: Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43:1095-1101, 1999 (Pubitemid 29144800)
8. D'Souza WD, Thames HD: Is the alpha/beta ratio for prostate cancer low? Int J Radiat Oncol Biol Phys 51:1-3, 2001
9. Dasu A: Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials? Clin Oncol (R Coll Radiol) 19:289-301, 2007
10. Martin T, Baltas D, Kurek R, et al: 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study. Strahlenther Onkol 180:225-232, 2004 (Pubitemid 38461547)
11. Vargas CE, Martinez AA, Boike TP, et al: High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: Results of a phase I to II study. Int J Radiat Oncol Biol Phys 66:416-423, 2006 (Pubitemid 44332728)
12. Yeoh EE, Holloway RH, Fraser RJ, et al: Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: Updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 66:1072-1083, 2006 (Pubitemid 44633501)
13. Kupelian PA, Willoughby TR, Reddy CA, et al: Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 68:1424-1430, 2007 (Pubitemid 47176809)
14. Grills IS, Martinez AA, Hollander M, et al: High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 171:1098-1104, 2004 (Pubitemid 38327535)
15. Martinez AA, Pataki I, Edmundson G, et al: Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: A feasibility report. Int J Radiat Oncol Biol Phys 49:61-69, 2001 (Pubitemid 32041277)
16. Yoshioka Y, Nose T, Yoshida K, et al: High-dose-rate brachytherapy as monotherapy for localized prostate cancer: A retrospective analysis with special focus on tolerance and chronic toxicity. Int J Radiat Oncol Biol Phys 56:213-220, 2003 (Pubitemid 36403694)
17. Yoshioka Y, Nose T, Yoshida K, et al: High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: Treatment description and preliminary results of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys 48:675-681, 2000
18. Fuller DB, Naitoh J, Lee C, et al: Virtual HDR CyberKnife treatment for localized prostatic carcinoma: Dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys 70:1588-1597, 2008 (Pubitemid 351417778)
19. Zietman AL, Bae K, Slater JD, et al: Randomized trial comparing conventional-dose with highdose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol 28:1106-1111, 2010
20. Kuban DA, Tucker SL, Dong L, et al: Longterm results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70:67-74, 2008 (Pubitemid 350251041)
21. Lotan Y, Stanfield J, Cho LC, et al: Efficacy of high dose per fraction radiation for implanted human prostate cancer in a nude mouse model. J Urol 175:1932-1936, 2006
22. Park C, Papiez L, Zhang S, et al: Universal survival curve and single fraction equivalent dose: Useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 70:847-852, 2008 (Pubitemid 351199730)
23. Madsen BL, Hsi RA, Pham HT, et al: Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results. Int J Radiat Oncol Biol Phys 67:1099-1105, 2007
24. Roach M 3rd, Marquez C, Yuo HS, et al: Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28:33-37, 1994 (Pubitemid 24012852)
25. Friberg S, Ruden BI: Hypofractionation in radiotherapy: An investigation of injured Swedish women, treated for cancer of the breast. Acta Oncol 48:822-831, 2009
26. Katz AJ, Santoro M, Ashley R, et al: Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol 10:1, 2010
27. King CR, Brooks JD, Gill H, et al: Stereotactic body radiotherapy for localized prostate cancer: Interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 73:1043-1048, 2009
28. Zietman AL, DeSilvio ML, Slater JD, et al: Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 294:1233-1239, 2005 (Pubitemid 41352111)
29. Sanda MG, Dunn RL, Michalski J, et al: Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358:1250-1261, 2008 (Pubitemid 351439226)
30. Rusthoven KE, Kavanagh BD, Burri SH, et al: Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 27:1579-1584, 2009